PL2949335T3 - Terapia octanem glatirameru podawanym z niewielką częstotliwością - Google Patents

Terapia octanem glatirameru podawanym z niewielką częstotliwością

Info

Publication number: PL2949335T3
Authority: PL; Poland
Prior art keywords: low frequency; glatiramer acetate; acetate therapy; frequency glatiramer; therapy
Prior art date: 2009-08-20

Application number

PL15171065T

Other languages

English (en)

Inventor

Ety Klinger

Original Assignee

Yeda Research & Development Company, Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-08-20

Filing date

2010-08-19

Publication date

2017-07-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43605835&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2949335(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-08-19 Application filed by Yeda Research & Development Company, Ltd. filed Critical Yeda Research & Development Company, Ltd.

2017-07-31 Publication of PL2949335T3 publication Critical patent/PL2949335T3/pl

Links

108010072051 Glatiramer Acetate Proteins 0.000 title 1
FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 title 1
229960003776 glatiramer acetate Drugs 0.000 title 1
238000002560 therapeutic procedure Methods 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Dermatology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Endocrinology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Oil, Petroleum & Natural Gas (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Biochemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Magnetic Resonance Imaging Apparatus (AREA)

PL15171065T 2009-08-20 2010-08-19 Terapia octanem glatirameru podawanym z niewielką częstotliwością PL2949335T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US27468709P	2009-08-20	2009-08-20
US33761210P	2010-02-11	2010-02-11
EP15171065.4A EP2949335B1 (en)	2009-08-20	2010-08-19	Low frequency glatiramer acetate therapy

Publications (1)

Publication Number	Publication Date
PL2949335T3 true PL2949335T3 (pl)	2017-07-31

Family

ID=43605835

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
PL10810282T PL2405749T3 (pl)	2009-08-20	2010-08-19	Terapia octanem glatirameru podawanym z niewielką częstością
PL15171065T PL2949335T3 (pl)	2009-08-20	2010-08-19	Terapia octanem glatirameru podawanym z niewielką częstotliwością
PL17157735T PL3199172T3 (pl)	2009-08-20	2010-08-19	Reżim dozowania w przypadku stwardnienia rozsianego
PL13166080T PL2630962T3 (pl)	2009-08-20	2010-08-19	Terapia octanem glatirameru podawanym z niewielką częstością

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL10810282T PL2405749T3 (pl)	2009-08-20	2010-08-19	Terapia octanem glatirameru podawanym z niewielką częstością

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
PL17157735T PL3199172T3 (pl)	2009-08-20	2010-08-19	Reżim dozowania w przypadku stwardnienia rozsianego
PL13166080T PL2630962T3 (pl)	2009-08-20	2010-08-19	Terapia octanem glatirameru podawanym z niewielką częstością

Country Status (34)

Country	Link
US (15)	US8399413B2 (pl)
EP (5)	EP2630962B1 (pl)
JP (3)	JP6038653B2 (pl)
KR (4)	KR20160038057A (pl)
CN (3)	CN105770855A (pl)
AR (2)	AR077896A1 (pl)
AT (1)	AT15421U1 (pl)
AU (1)	AU2010284666B2 (pl)
BR (1)	BR112012003730A2 (pl)
CA (2)	CA2760802C (pl)
CY (2)	CY1114537T1 (pl)
CZ (2)	CZ29723U1 (pl)
DE (1)	DE202010018377U1 (pl)
DK (5)	DK3199172T3 (pl)
EA (3)	EA032283B1 (pl)
ES (4)	ES2689711T3 (pl)
HK (4)	HK1165959A1 (pl)
HR (4)	HRP20130677T1 (pl)
HU (2)	HUE031282T2 (pl)
IL (3)	IL218106A0 (pl)
LT (3)	LT2949335T (pl)
ME (2)	ME01536B (pl)
MX (1)	MX2012002082A (pl)
NZ (1)	NZ598661A (pl)
PL (4)	PL2405749T3 (pl)
PT (4)	PT3199172T (pl)
RS (2)	RS55607B1 (pl)
SG (2)	SG178495A1 (pl)
SI (4)	SI3199172T1 (pl)
SK (1)	SK501352015U1 (pl)
SM (1)	SMT201700057B (pl)
TW (3)	TWI477273B (pl)
UA (1)	UA103699C2 (pl)
WO (1)	WO2011022063A1 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2527760T3 (es) *	1998-07-23	2015-01-29	Yeda Research And Development Co., Ltd.	Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US8077333B2 (en) *	2002-09-09	2011-12-13	Canon Kabushiki Kaisha	Printing control apparatus and printing control method
LT2949335T (lt) *	2009-08-20	2017-03-27	Yeda Research & Development Company, Ltd.	Žemo dažnio glatiramero acetato terapija
USRE49251E1 (en)	2010-01-04	2022-10-18	Mapi Pharma Ltd.	Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) *	2010-03-16	2014-06-24	Teva Pharmaceutical Industries, Ltd.	Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
BR112013008573A2 (pt)	2010-10-11	2016-07-12	Teva Pharma	citocinas biomarcadoras como indicadores de resposta clínica a acetato de glatirâmer.
EA201490749A1 (ru)	2011-10-10	2014-09-30	Тева Фармасьютикал Индастриз Лтд.	Однонуклеотидные полиморфизмы, полезные для прогнозирования клинической реакции на глатирамера ацетат
EP2906719A4 (en)	2012-10-10	2016-11-09	Teva Pharma	PREDICTIVE BIOMARKER FOR CLINICAL REACTION FOR GLATIRAMERACETATE
JP2016504039A (ja) *	2013-01-04	2016-02-12	テバファーマシューティカルインダストリーズリミティド	グラチラマーアセテート関連医薬品の特性決定
UY35790A (es)	2013-10-21	2015-05-29	Teva Pharma	Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN103641897B (zh) *	2013-11-27	2017-01-04	深圳翰宇药业股份有限公司	一种合成醋酸格拉替雷的方法
US9763992B2 (en)	2014-02-13	2017-09-19	Father Flanagan's Boys' Home	Treatment of noise induced hearing loss
WO2015195605A1 (en) *	2014-06-17	2015-12-23	Teva Pharmaceutical Industries Ltd.	Transmucosal delivery of glatiramer acetate by oral patches
CN104844697B (zh) *	2014-09-26	2018-10-23	深圳翰宇药业股份有限公司	醋酸格拉替雷的制备方法
US9155775B1 (en) *	2015-01-28	2015-10-13	Teva Pharmaceutical Industries, Ltd.	Process for manufacturing glatiramer acetate product
CN107550853B (zh) *	2016-06-30	2020-06-12	深圳翰宇药业股份有限公司	一种醋酸格拉替雷注射液的制备方法
LT3506921T (lt)	2016-08-31	2023-08-10	Mapi Pharma Ltd	Ilgesnio atpalaidavimo sistemos, kuriose yra glatiramero acetato
EP3551046B1 (en)	2016-12-07	2023-07-19	Biora Therapeutics, Inc.	Gastrointestinal tract detection methods, devices and systems
CA3050086A1 (en) *	2017-03-26	2018-10-04	Mapi Pharma Ltd.	Glatiramer depot systems for treating progressive forms of multiple sclerosis
CN110996983A (zh)	2017-06-26	2020-04-10	巴斯德研究所	清除hiv储库并降低病毒载量的治疗
US20200306516A1 (en)	2017-08-14	2020-10-01	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof
KR102519053B1 (ko)	2021-02-08	2023-04-06	건국대학교 산학협력단	염산가스의 농도 측정을 위한 수분 전처리 시스템
KR102519054B1 (ko)	2021-03-12	2023-04-06	건국대학교 산학협력단	나피온 드라이어와 수분 전처리장치의 결합시스템
CA3221343A1 (en) *	2021-10-11	2023-04-20	Allitia DIBERNARDO	Methods of treating multiple sclerosis

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL36670A (en)	1971-04-21	1974-09-10	Sela M	Therapeutic basic copolymers of amino acids
DE3673317D1 (de)	1985-10-11	1990-09-13	Duphar Int Res	Automatische spritze.
US5981485A (en)	1997-07-14	1999-11-09	Genentech, Inc.	Human growth hormone aqueous formulation
IL113812A (en)	1994-05-24	2000-06-29	Yeda Res & Dev	Copolymer-1 pharmaceutical compositions containing it and its use
IL119989A0 (en)	1997-01-10	1997-04-15	Yeda Res & Dev	Pharmaceutical compositions for oral treatment of multiple sclerosis
US6214791B1 (en)	1997-01-10	2001-04-10	Yeda Research And Development Co. Ltd.	Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
US6454746B1 (en)	1997-06-04	2002-09-24	Eli Lilly And Company	Medication delivery apparatus
IL140592A0 (en)	1998-07-23	2002-02-10	Harvard College	Synthetic peptides and methods of use for autoimmune disease therapies
ES2527760T3 (es)	1998-07-23	2015-01-29	Yeda Research And Development Co., Ltd.	Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
EP1098902A4 (en)	1998-07-23	2002-07-24	Yeda Res & Dev	TREATMENT OF AUTOIMMUNE DISEASES BY COPOLYMER 1 AND SIMILAR COPOLYMERS AND PEPTIDES
PT2239269E (pt)	1998-09-25	2013-04-09	Yeda Res & Dev	Uso de péptidos derivados de copolímero 1 como marcadores de peso molecular
US6800287B2 (en)	1998-09-25	2004-10-05	Yeda Research And Development Co., Ltd.	Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6514938B1 (en)	1998-09-25	2003-02-04	Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science	Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
AU6281599A (en)	1998-10-02	2000-04-26	Yeda Research And Development Co. Ltd.	Alternate day administration of copolymer 1 for treating autoimmune diseases
AU775073C (en)	1998-11-12	2007-05-03	Yeda Research And Development Co. Ltd.	Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD
ES2330301T3 (es)	1999-08-27	2009-12-09	Genentech, Inc.	Dosificaciones para tratamiento con anticuerpos anti-erbb2.
US6844314B2 (en)	2000-01-20	2005-01-18	Yeda Research Development Co., Ltd.	Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
US7022663B2 (en)	2000-02-18	2006-04-04	Yeda Research And Development Co., Ltd.	Oral, nasal and pulmonary dosage formulations of copolymer 1
ATE329608T1 (de)	2000-02-18	2006-07-15	Yeda Res & Dev	Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
HUP0302333A3 (en)	2000-06-05	2005-07-28	Teva Pharma	The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders
US20020077278A1 (en)	2000-06-05	2002-06-20	Yong V. Wee	Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
IL150801A0 (en)	2000-06-07	2003-02-12	Yeda Res & Dev	The use of copolymer 1 and related peptides and polypeptides for protecting central nervous system cells from glutamate toxicity
WO2002076503A1 (en)	2000-06-20	2002-10-03	Mayo Foundation For Medical Education And Research	Treatment of central nervous system diseases by antibodies against glatiramer acetate
CN1308683C (zh)	2001-12-04	2007-04-04	特瓦制药工业有限公司	测量醋酸格拉默功效的方法
WO2004043995A2 (en)	2002-11-13	2004-05-27	Apotex Pharmachem Inc.	Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
AU2003275895B2 (en)	2002-11-25	2009-02-05	Tecpharma Licensing Ag	Auto-injector comprising a resettable releasing safety device
US7274347B2 (en)	2003-06-27	2007-09-25	Texas Instruments Incorporated	Prevention of charge accumulation in micromirror devices through bias inversion
MXPA05007711A (es)	2003-01-21	2005-09-30	Yeda Res & Dev	Copolimero 1 para el tratamiento de enfermedades inflamatorias del intestino.
CA2518079A1 (en)	2003-03-04	2004-10-28	Teva Pharmaceutical Industries, Ltd.	Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
US7968511B2 (en) *	2003-05-14	2011-06-28	Teva Pharmaceutical Industries, Ltd.	Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
US20050170004A1 (en)	2003-10-31	2005-08-04	Vered Rosenberger	Nanoparticles for drug delivery
HUP0303779A2 (en) *	2003-11-20	2006-02-28	Richter Gedeon Vegyeszet	Pharmaceutical compositions containing hyaluronan complex for the treatment of sclerosis multiplex
CA2558380A1 (en)	2004-03-03	2005-09-15	Teva Pharmaceutical Industries, Ltd.	Combination therapy with glatiramer acetate and riluzole
CN101022728B (zh) *	2004-03-25	2012-08-08	詹森药业有限公司	咪唑化合物
US7655221B2 (en)	2004-05-07	2010-02-02	Peptimmune, Inc.	Methods of treating disease with random copolymers
US20060194725A1 (en)	2004-05-07	2006-08-31	James Rasmussen	Methods of treating disease with random copolymers
RU2410115C2 (ru)	2004-05-07	2011-01-27	Пептиммьюн, Инк.	Способы лечения заболеваний с помощью статистических сополимеров
EP1761276B1 (en) *	2004-06-25	2013-07-24	ID Biomedical Corporation of Quebec	Compositions and methods for treating neurological disorders
US20090048181A1 (en) *	2004-09-02	2009-02-19	Schipper Hyman M	Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
US7560100B2 (en)	2004-09-09	2009-07-14	Yeda Research And Development Co., Ltd.	Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases
PL2361924T3 (pl)	2004-09-09	2014-08-29	Teva Pharma	Proces przygotowania mieszanin octanu trifluoroacetyloglatirameru z zastosowaniem oczyszczonego kwasu bromowodorowego
AR052321A1 (es)	2004-10-29	2007-03-14	Sandoz Ag	Procesos para la preparacion de un polipeptido
CA2594022A1 (en)	2005-02-02	2006-08-10	Teva Pharmaceutical Industries Ltd.	Process for producing polypeptide mixtures using hydrogenolysis
US20100167983A1 (en)	2007-10-22	2010-07-01	Teva Pharmaceutical Industries, Ltd.	Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
US20080261894A1 (en)	2005-02-17	2008-10-23	Rivka Kreitman	Combination Therapy with Glatiramer Acetate and Rasagiline for the Treatment of Multiple Sclerosis
EP1891233A4 (en)	2005-04-25	2010-03-24	Yeda Res & Dev	MARKERS ASSOCIATED WITH THERAPY EFFECTIVENESS OF GLATIRAMERATE ACETATE
WO2007030573A2 (en)	2005-09-09	2007-03-15	Yeda Research And Development Co. Ltd.	Polypeptides useful for molecular weight determinations
WO2007081975A2 (en) *	2006-01-11	2007-07-19	Teva Pharmaceutical Industries, Ltd.	Method of treating multiple sclerosis
US20080118553A1 (en)	2006-06-12	2008-05-22	Anton Frenkel	Tannate salt form of polypeptide mixtures, their preparation and use
KR101440795B1 (ko)	2006-06-30	2014-09-22	애브비 바이오테크놀로지 리미티드	자동 주사 장치
EP2143728A1 (en)	2006-07-05	2010-01-13	Momenta Pharmaceuticals, Inc.	Improved process for the preparation of copolymer-1
CN101883586A (zh) *	2007-10-01	2010-11-10	约翰斯霍普金斯大学	使用环磷酰胺治疗神经性自身免疫疾病
MX2010005676A (es)	2007-11-28	2010-08-06	Teva Pharma	Metodo para retrasar el comienzo de esclerosis multiple clinicamente definida.
CA2697570C (en)	2009-07-15	2011-11-01	Teva Pharmaceutical Industries, Ltd.	Reduced volume formulation of glatiramer acetate and methods of administration
US8920373B2 (en)	2009-07-15	2014-12-30	Teva Pharmaceutical Industries, Ltd.	Reduced volume formulation of glatiramer acetate and methods of administration
LT2949335T (lt) *	2009-08-20	2017-03-27	Yeda Research & Development Company, Ltd.	Žemo dažnio glatiramero acetato terapija
US8759302B2 (en)	2010-03-16	2014-06-24	Teva Pharmaceutical Industries, Ltd.	Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
BR112013008573A2 (pt)	2010-10-11	2016-07-12	Teva Pharma	citocinas biomarcadoras como indicadores de resposta clínica a acetato de glatirâmer.
EA201490749A1 (ru)	2011-10-10	2014-09-30	Тева Фармасьютикал Индастриз Лтд.	Однонуклеотидные полиморфизмы, полезные для прогнозирования клинической реакции на глатирамера ацетат
EP2906719A4 (en)	2012-10-10	2016-11-09	Teva Pharma	PREDICTIVE BIOMARKER FOR CLINICAL REACTION FOR GLATIRAMERACETATE
JP2016504039A (ja)	2013-01-04	2016-02-12	テバファーマシューティカルインダストリーズリミティド	グラチラマーアセテート関連医薬品の特性決定
CA2903127A1 (en)	2013-03-12	2014-10-09	Teva Pharmaceutical Industries Ltd.	Rituximab induction therapy followed by glatiramer acetate therapy

2010
- 2010-08-19 LT LTEP15171065.4T patent/LT2949335T/lt unknown
- 2010-08-19 DK DK17157735.6T patent/DK3199172T3/en active
- 2010-08-19 PT PT17157735T patent/PT3199172T/pt unknown
- 2010-08-19 CZ CZ2015-31885U patent/CZ29723U1/cs not_active IP Right Cessation
- 2010-08-19 JP JP2012525530A patent/JP6038653B2/ja active Active
- 2010-08-19 PT PT131660805T patent/PT2630962T/pt unknown
- 2010-08-19 ES ES17157735.6T patent/ES2689711T3/es active Active
- 2010-08-19 CA CA2760802A patent/CA2760802C/en active Active
- 2010-08-19 KR KR1020167006001A patent/KR20160038057A/ko not_active Application Discontinuation
- 2010-08-19 EP EP13166080.5A patent/EP2630962B1/en not_active Revoked
- 2010-08-19 DK DK15171065.4T patent/DK2949335T3/en active
- 2010-08-19 PL PL10810282T patent/PL2405749T3/pl unknown
- 2010-08-19 EP EP10810282.3A patent/EP2405749B1/en not_active Revoked
- 2010-08-19 SI SI201031740T patent/SI3199172T1/sl unknown
- 2010-08-19 HU HUE15171065A patent/HUE031282T2/hu unknown
- 2010-08-19 SG SG2012011425A patent/SG178495A1/en unknown
- 2010-08-19 AT ATGM50231/2015U patent/AT15421U1/de not_active IP Right Cessation
- 2010-08-19 EA EA201400394A patent/EA032283B1/ru unknown
- 2010-08-19 LT LTEP13166080.5T patent/LT2630962T/lt unknown
- 2010-08-19 CN CN201610104429.4A patent/CN105770855A/zh active Pending
- 2010-08-19 EP EP17157735.6A patent/EP3199172B1/en not_active Revoked
- 2010-08-19 UA UAA201203259A patent/UA103699C2/ru unknown
- 2010-08-19 SG SG10201405806SA patent/SG10201405806SA/en unknown
- 2010-08-19 EA EA201691347A patent/EA032287B1/ru unknown
- 2010-08-19 AU AU2010284666A patent/AU2010284666B2/en not_active Withdrawn - After Issue
- 2010-08-19 SI SI201030270T patent/SI2405749T1/sl unknown
- 2010-08-19 SI SI201031375A patent/SI2949335T1/sl unknown
- 2010-08-19 ES ES10810282T patent/ES2424692T3/es active Active
- 2010-08-19 KR KR1020127007115A patent/KR20120090044A/ko active Search and Examination
- 2010-08-19 PT PT151710654T patent/PT2949335T/pt unknown
- 2010-08-19 HU HUE17157735A patent/HUE039335T2/hu unknown
- 2010-08-19 CN CN201610878988.0A patent/CN107050423A/zh active Pending
- 2010-08-19 EP EP18179172.4A patent/EP3409286B1/en active Active
- 2010-08-19 US US12/806,684 patent/US8399413B2/en active Active
- 2010-08-19 MX MX2012002082A patent/MX2012002082A/es active IP Right Grant
- 2010-08-19 LT LTEP17157735.6T patent/LT3199172T/lt unknown
- 2010-08-19 CA CA2876966A patent/CA2876966A1/en not_active Abandoned
- 2010-08-19 RS RS20170053A patent/RS55607B1/sr unknown
- 2010-08-19 WO PCT/US2010/002283 patent/WO2011022063A1/en active Application Filing
- 2010-08-19 CZ CZ2016-33036U patent/CZ30474U1/cs not_active IP Right Cessation
- 2010-08-19 DK DK10810282.3T patent/DK2405749T3/da active
- 2010-08-19 DE DE202010018377.4U patent/DE202010018377U1/de not_active Ceased
- 2010-08-19 PL PL15171065T patent/PL2949335T3/pl unknown
- 2010-08-19 PL PL17157735T patent/PL3199172T3/pl unknown
- 2010-08-19 PT PT108102823T patent/PT2405749E/pt unknown
- 2010-08-19 ES ES15171065.4T patent/ES2612001T4/es active Active
- 2010-08-19 ME MEP-2013-81A patent/ME01536B/me unknown
- 2010-08-19 KR KR1020177031069A patent/KR20170123354A/ko not_active Application Discontinuation
- 2010-08-19 SI SI201031719T patent/SI2630962T1/sl unknown
- 2010-08-19 ES ES13166080.5T patent/ES2688873T3/es active Active
- 2010-08-19 CN CN2010800369660A patent/CN102625657A/zh active Pending
- 2010-08-19 RS RS20130293A patent/RS52885B/en unknown
- 2010-08-19 ME MEP-2017-17A patent/ME02662B/me unknown
- 2010-08-19 BR BR112012003730-7A patent/BR112012003730A2/pt not_active Application Discontinuation
- 2010-08-19 DK DK13166080.5T patent/DK2630962T3/en active
- 2010-08-19 KR KR1020147012452A patent/KR20140061559A/ko not_active Application Discontinuation
- 2010-08-19 EP EP15171065.4A patent/EP2949335B1/en not_active Revoked
- 2010-08-19 PL PL13166080T patent/PL2630962T3/pl unknown
- 2010-08-19 EA EA201270292A patent/EA019998B9/ru not_active IP Right Cessation
- 2010-08-19 NZ NZ598661A patent/NZ598661A/xx unknown
- 2010-08-20 TW TW099128023A patent/TWI477273B/zh active
- 2010-08-20 TW TW106100768A patent/TW201733575A/zh unknown
- 2010-08-20 AR ARP100103062A patent/AR077896A1/es not_active Application Discontinuation
- 2010-08-20 TW TW103138861A patent/TWI643614B/zh not_active IP Right Cessation
2011
- 2011-11-30 US US13/308,299 patent/US8232250B2/en active Active
2012
- 2012-02-14 IL IL218106A patent/IL218106A0/en active IP Right Grant
- 2012-07-12 HK HK12106867.3A patent/HK1165959A1/xx not_active IP Right Cessation
2013
- 2013-02-19 US US13/770,677 patent/US8969302B2/en not_active Expired - Fee Related
- 2013-07-17 HR HRP20130677AT patent/HRP20130677T1/hr unknown
- 2013-07-22 CY CY20131100615T patent/CY1114537T1/el unknown
2014
- 2014-02-26 HK HK19100376.3A patent/HK1258008A1/zh unknown
- 2014-06-30 IL IL233468A patent/IL233468A0/en unknown
2015
- 2015-01-12 AR ARP150100073A patent/AR099078A2/es not_active Application Discontinuation
- 2015-02-24 US US14/630,326 patent/US20150164977A1/en not_active Abandoned
- 2015-03-30 US US14/673,257 patent/US9402874B2/en active Active
- 2015-05-13 JP JP2015098415A patent/JP6169644B2/ja active Active
- 2015-05-22 US US14/720,556 patent/US9155776B2/en not_active Expired - Fee Related
- 2015-12-18 SK SK50135-2015U patent/SK501352015U1/sk unknown
2016
- 2016-01-06 DK DK201600003U patent/DK201600003Y3/da not_active IP Right Cessation
- 2016-05-06 US US15/148,215 patent/US20160250251A1/en not_active Abandoned
- 2016-06-01 HK HK16106219.4A patent/HK1218250A1/zh not_active IP Right Cessation
- 2016-12-01 HK HK16113727A patent/HK1225310A1/zh unknown
- 2016-12-15 US US15/380,579 patent/US20170095523A1/en not_active Abandoned
2017
- 2017-01-13 HR HRP20170056TT patent/HRP20170056T2/hr unknown
- 2017-01-16 CY CY20171100052T patent/CY1118529T1/el unknown
- 2017-01-25 SM SM201700057T patent/SMT201700057B/it unknown
- 2017-02-22 JP JP2017031335A patent/JP2017132773A/ja not_active Withdrawn
- 2017-03-27 US US15/469,758 patent/US20170196803A1/en not_active Abandoned
- 2017-04-26 IL IL251943A patent/IL251943A0/en unknown
- 2017-07-05 US US15/642,201 patent/US20170296464A1/en not_active Abandoned
- 2017-11-13 US US15/811,495 patent/US20180064639A1/en not_active Abandoned
2018
- 2018-02-28 US US15/908,441 patent/US20180185274A1/en not_active Abandoned
- 2018-06-27 US US16/020,591 patent/US20180311149A1/en not_active Abandoned
- 2018-08-06 HR HRP20181254TT patent/HRP20181254T1/hr unknown
- 2018-08-06 HR HRP20181253TT patent/HRP20181253T1/hr unknown
- 2018-10-19 US US16/165,541 patent/US20190054013A1/en not_active Abandoned
2019
- 2019-02-11 US US16/272,786 patent/US20190175494A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HRP20170056T1 (hr)	2017-03-24
US20170296464A1 (en)	2017-10-19
EA032283B1 (ru)	2019-05-31
JP6038653B2 (ja)	2016-12-07
IL251943A0 (en)	2017-06-29
HK1165959A1 (en)	2012-10-19
TWI643614B (zh)	2018-12-11
EP2405749B1 (en)	2013-05-08
US20180185274A1 (en)	2018-07-05
DK3199172T3 (en)	2018-10-08
AU2010284666A1 (en)	2011-09-22
EP3199172A8 (en)	2017-10-11
RS55607B1 (sr)	2017-06-30
SI2949335T1 (sl)	2017-05-31
CZ30474U1 (cs)	2017-03-14
RS52885B (en)	2014-02-28
HK1258008A1 (zh)	2019-11-01
HRP20181253T1 (hr)	2018-11-02
NZ598661A (en)	2013-02-22
SG10201405806SA (en)	2014-11-27
US8399413B2 (en)	2013-03-19
TWI477273B (zh)	2015-03-21
PT2949335T (pt)	2017-02-03
EP3199172B1 (en)	2018-07-11
HUE039335T2 (hu)	2018-12-28
EA201691347A3 (ru)	2016-11-30
US20150202247A1 (en)	2015-07-23
ES2424692T3 (es)	2013-10-07
EA201400394A1 (ru)	2014-10-30
EP2949335B1 (en)	2017-01-04
ME02662B (me)	2017-06-20
EP2405749A4 (en)	2012-08-22
IL218106A0 (en)	2012-04-30
PL2405749T3 (pl)	2013-12-31
LT2949335T (lt)	2017-03-27
IL233468A0 (en)	2014-08-31
EP2630962B1 (en)	2018-06-27
SK501352015U1 (sk)	2017-07-03
DE202010018377U1 (de)	2016-02-25
US20130165387A1 (en)	2013-06-27
SI3199172T1 (sl)	2018-10-30
US9155776B2 (en)	2015-10-13
DK2949335T3 (en)	2017-07-31
US20120071416A1 (en)	2012-03-22
CN105770855A (zh)	2016-07-20
US9402874B2 (en)	2016-08-02
ES2612001T3 (es)	2017-05-11
EP2630962A1 (en)	2013-08-28
PL3199172T3 (pl)	2019-01-31
TW201521718A (zh)	2015-06-16
CN107050423A (zh)	2017-08-18
LT2630962T (lt)	2018-10-25
SI2630962T1 (sl)	2018-10-30
EP3409286B1 (en)	2020-08-12
AR077896A1 (es)	2011-09-28
CA2876966A1 (en)	2011-02-24
US8232250B2 (en)	2012-07-31
PT2405749E (pt)	2013-07-22
US20180064639A1 (en)	2018-03-08
EA019998B1 (ru)	2014-07-30
KR20160038057A (ko)	2016-04-06
KR20120090044A (ko)	2012-08-16
EA201691347A2 (ru)	2016-10-31
CY1118529T1 (el)	2017-07-12
US20170196803A1 (en)	2017-07-13
HUE031282T2 (hu)	2017-06-28
DK201600003Y3 (da)	2016-02-12
HK1218250A1 (zh)	2017-02-10
EA019998B9 (ru)	2016-01-29
US20150164977A1 (en)	2015-06-18
EA032287B1 (ru)	2019-05-31
SMT201700057B (it)	2017-03-08
HRP20170056T2 (hr)	2017-12-15
EP3409286A1 (en)	2018-12-05
KR20170123354A (ko)	2017-11-07
CN102625657A (zh)	2012-08-01
SG178495A1 (en)	2012-03-29
JP6169644B2 (ja)	2017-07-26
US20150250845A1 (en)	2015-09-10
AU2010284666B2 (en)	2012-12-06
JP2015187125A (ja)	2015-10-29
BR112012003730A2 (pt)	2020-07-21
ES2688873T3 (es)	2018-11-07
EP3199172A1 (en)	2017-08-02
HRP20181254T1 (hr)	2019-01-25
EP2405749A1 (en)	2012-01-18
HRP20130677T1 (en)	2013-10-11
US8969302B2 (en)	2015-03-03
TW201733575A (zh)	2017-10-01
CA2760802A1 (en)	2011-02-24
PT3199172T (pt)	2018-10-18
CA2760802F (en)	2011-02-24
CA2760802C (en)	2016-01-12
AR099078A2 (es)	2016-06-29
HK1225310A1 (zh)	2017-09-08
AT15421U1 (de)	2017-08-15
ES2689711T3 (es)	2018-11-15
CY1114537T1 (el)	2016-10-05
EA201270292A1 (ru)	2012-12-28
DK2405749T3 (da)	2013-07-15
PL2630962T3 (pl)	2018-12-31
WO2011022063A1 (en)	2011-02-24
ME01536B (me)	2014-04-20
PT2630962T (pt)	2018-08-01
LT3199172T (lt)	2018-10-25
US20180311149A1 (en)	2018-11-01
JP2013502415A (ja)	2013-01-24
DK2630962T3 (en)	2018-07-23
JP2017132773A (ja)	2017-08-03
US20110046065A1 (en)	2011-02-24
UA103699C2 (ru)	2013-11-11
KR20140061559A (ko)	2014-05-21
SI2405749T1 (sl)	2013-10-30
US20160250251A1 (en)	2016-09-01
US20190054013A1 (en)	2019-02-21
DK201600003U1 (da)	2016-01-22
EP2949335A1 (en)	2015-12-02
TW201119645A (en)	2011-06-16
CZ29723U1 (cs)	2016-08-30
MX2012002082A (es)	2012-08-23
US20190175494A1 (en)	2019-06-13
ES2612001T4 (es)	2018-02-07
US20170095523A1 (en)	2017-04-06

Publication	Publication Date	Title
HRP20181253T1 (hr)	2018-11-02	Terapija male učestalosti glatiramer acetatom
HK1214547A1 (zh)	2016-07-29	吸入器
HK1165342A1 (zh)	2012-10-05	吸入器
IL217969A (en)	2014-02-27	inhaler
AU331057S (en)	2010-05-28	Inhaler
GB0914738D0 (en)	2009-09-30	Inhalers
GB0922519D0 (en)	2010-02-10	Inhaler
GB0914819D0 (en)	2009-09-30	Food dressing therapy
GB0903318D0 (en)	2009-04-08	Medicament
GB0901902D0 (en)	2009-03-11	Medicament
GB0903319D0 (en)	2009-04-08	Therapy
GB0903321D0 (en)	2009-04-08	Therapy
GB0914820D0 (en)	2009-09-30	WATerian therapy
GB0921244D0 (en)	2010-01-20	Therapy
GB0910919D0 (en)	2009-08-05	Inhaler
GB0922546D0 (en)	2010-02-10	Inhaler
GB0922545D0 (en)	2010-02-10	Inhaler